View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Exhibitor Product Listings<br />
4S Dawn Clinical Software<br />
Some key problems with monitoring DMARD therapy are:<br />
• Time consumed in monitoring of laboratory test results, which must be carried out in an exacting manner<br />
• Not <strong>for</strong>getting to follow up on actions decided <strong>for</strong> the patient<br />
• Auditing therapy management<br />
Dawn DMARD software overcomes this by:<br />
• Rigorously monitoring test results automatically<br />
• Produces electronic alerts<br />
• Providing an auditing/report writing facility<br />
Abbott<br />
HUMIRA ®▼ (adalimumab – Abbott Laboratories Ltd) is a fully human monoclonal antibody, indicated <strong>for</strong> the treatment of<br />
moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs including<br />
methotrexate has been inadequate. HUMIRA ®▼ can be given in combination with MTX or as monotherapy in case of<br />
intolerance to MTX or when continued treatment with MTX is inappropriate.<br />
Actelion<br />
Tracleer the first dual Endothelin receptor antagonist, a significant advance in the treatment of Pulmonary Arterial<br />
Hypertension (PAH) related to connective tissue disease.<br />
• Tracleer is the only licensed treatment <strong>for</strong> Scleroderma patients with PAH<br />
• Tracleer significantly improves exercise capacity<br />
• Tracleer significantly decreases the rate of clinical worsening<br />
• Tracleer has a convenient b.d. dosage.<br />
For further in<strong>for</strong>mation call 0845-0750555. Reference: Tracleer SmPC June 2003<br />
arc<br />
<strong>The</strong> Arthritis Research Campaign (a r c) is the fourth-largest medical research charity in the UK with an annual income in 2002-3<br />
of £23.5 million. a r c funds research into all <strong>for</strong>ms of arthritis and related conditions, and also provides in<strong>for</strong>mation to the public<br />
(including more than 80 patient booklets) and health professionals. a r c also funds a variety of fellowships and bursaries.<br />
ARMA<br />
<strong>The</strong> Arthritis and Musculoskeletal Alliance (ARMA) is the UK umbrella organisation bringing together 27 members including<br />
support groups, research organisations and medical/ non-medical professionals’ societies. Visit our stand to pick up<br />
in<strong>for</strong>mation on our Member organisations and find out about our consultation on Standards of Care <strong>for</strong> people with MSCs.<br />
Rheumatologists have been closely involved in this project and we want to hear your views on the standards.<br />
Arthritis Care<br />
Arthritis Care is the UK’s largest voluntary organisation <strong>for</strong> people with all types of arthritis. Our aim is to empower<br />
people to take control of their arthritis, their organisation and their lives. We offer a range of services including helplines,<br />
publications, self-management and hotels. We also campaign to ensure the voice of people with arthritis is heard at both a<br />
national and local level.<br />
Aventis/Alliance <strong>for</strong> Better Bone<br />
Actonel ® (risedronate sodium), a bisphosphonate produced by <strong>The</strong> Alliance For Better Bone Health (Procter and Gamble<br />
/ Aventis). <strong>The</strong> Alliance is committed to the timely identification and treatment of postmenopausal<br />
osteoporosis.<br />
Arava ® (leflunomide) produced by Aventis<br />
A disease-modifying antirheumatic drug (DMARD) that represents a significant advance in the treatment of adult patients with<br />
active rheumatoid arthritis.<br />
84